120 related articles for article (PubMed ID: 36623445)
21. Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer.
Rafiei S; Gui B; Wu J; Liu XS; Kibel AS; Jia L
Mol Cancer Res; 2019 Jan; 17(1):263-276. PubMed ID: 30224544
[TBL] [Abstract][Full Text] [Related]
22. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
Lakshmana G; Baniahmad A
Int J Cancer; 2019 Apr; 144(8):1775-1779. PubMed ID: 30125354
[TBL] [Abstract][Full Text] [Related]
23. DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor.
Jing Y; Nguyen MM; Wang D; Pascal LE; Guo W; Xu Y; Ai J; Deng FM; Masoodi KZ; Yu X; Zhang J; Nelson JB; Xia S; Wang Z
Oncogene; 2018 Feb; 37(5):638-650. PubMed ID: 28991234
[TBL] [Abstract][Full Text] [Related]
24. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
Ylitalo EB; Thysell E; Jernberg E; Lundholm M; Crnalic S; Egevad L; Stattin P; Widmark A; Bergh A; Wikström P
Eur Urol; 2017 May; 71(5):776-787. PubMed ID: 27497761
[TBL] [Abstract][Full Text] [Related]
25. The expression profile and heterogeneity analysis of ERG in 633 consecutive prostate cancers from a single center.
Nie L; Pan X; Zhang M; Yin X; Gong J; Chen X; Xu M; Zhou Q; Chen N
Prostate; 2019 Jun; 79(8):819-825. PubMed ID: 30900303
[TBL] [Abstract][Full Text] [Related]
26. TRIP13 is a predictor for poor prognosis and regulates cell proliferation, migration and invasion in prostate cancer.
Dong L; Ding H; Li Y; Xue D; Li Z; Liu Y; Zhang T; Zhou J; Wang P
Int J Biol Macromol; 2019 Jan; 121():200-206. PubMed ID: 30267820
[TBL] [Abstract][Full Text] [Related]
27. CRISPR screening of E3 ubiquitin ligases reveals Ring Finger Protein 185 as a novel tumor suppressor in glioblastoma repressed by promoter hypermethylation and miR-587.
Lin K; Shen SH; Lu F; Zheng P; Wu S; Liao J; Jiang X; Zeng G; Wei D
J Transl Med; 2022 Feb; 20(1):96. PubMed ID: 35183197
[TBL] [Abstract][Full Text] [Related]
28. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
[TBL] [Abstract][Full Text] [Related]
29. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
30. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S
Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300
[TBL] [Abstract][Full Text] [Related]
31. The combined effect of epigenetic inhibitors for LSD1 and BRD4 alters prostate cancer growth and invasion.
Wang J; Yu Q; Qiu Z; Dai T; Wang S; Yang X; Evers BM; Wu Y
Aging (Albany NY); 2020 Jan; 12(1):397-415. PubMed ID: 31901895
[TBL] [Abstract][Full Text] [Related]
32. RNF8 up-regulates AR/ARV7 action to contribute to advanced prostate cancer progression.
Zhou T; Wang S; Song X; Liu W; Dong F; Huo Y; Zou R; Wang C; Zhang S; Liu W; Sun G; Lin L; Zeng K; Dong X; Guo Q; Yi F; Wang Z; Li X; Jiang B; Cao L; Zhao Y
Cell Death Dis; 2022 Apr; 13(4):352. PubMed ID: 35428760
[TBL] [Abstract][Full Text] [Related]
33. Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression.
Saraon P; Cretu D; Musrap N; Karagiannis GS; Batruch I; Drabovich AP; van der Kwast T; Mizokami A; Morrissey C; Jarvi K; Diamandis EP
Mol Cell Proteomics; 2013 Jun; 12(6):1589-601. PubMed ID: 23443136
[TBL] [Abstract][Full Text] [Related]
34. MiR-515-5p acts as a tumor suppressor via targeting TRIP13 in prostate cancer.
Zhang X; Zhou J; Xue D; Li Z; Liu Y; Dong L
Int J Biol Macromol; 2019 May; 129():227-232. PubMed ID: 30685303
[TBL] [Abstract][Full Text] [Related]
35. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
36. Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.
Dalal K; Ban F; Li H; Morin H; Roshan-Moniri M; Tam KJ; Shepherd A; Sharma A; Peacock J; Carlson ML; LeBlanc E; Perez C; Duong F; Ong CJ; Rennie PS; Cherkasov A
Cancer Lett; 2018 Nov; 437():35-43. PubMed ID: 30165195
[TBL] [Abstract][Full Text] [Related]
37. Averaged differential expression for the discovery of biomarkers in the blood of patients with prostate cancer.
Bai VU; Hwang O; Divine GW; Barrack ER; Menon M; Reddy GP; Hwang C
PLoS One; 2012; 7(4):e34875. PubMed ID: 22493721
[TBL] [Abstract][Full Text] [Related]
38. Targeting the KIF4A/AR Axis to Reverse Endocrine Therapy Resistance in Castration-resistant Prostate Cancer.
Cao Q; Song Z; Ruan H; Wang C; Yang X; Bao L; Wang K; Cheng G; Xu T; Xiao W; Xiong Z; Liu D; Yang M; Zhou D; Yang H; Chen K; Zhang X
Clin Cancer Res; 2020 Mar; 26(6):1516-1528. PubMed ID: 31796514
[TBL] [Abstract][Full Text] [Related]
39. The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling.
Correa RG; Krajewska M; Ware CF; Gerlic M; Reed JC
Oncotarget; 2014 Mar; 5(6):1666-82. PubMed ID: 24681825
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer.
Gupta S; Vanderbilt C; Abida W; Fine SW; Tickoo SK; Al-Ahmadie HA; Chen YB; Sirintrapun SJ; Chadalavada K; Nanjangud GJ; Bialik A; Morris MJ; Scher HI; Ladanyi M; Reuter VE; Gopalan A
Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):507-516. PubMed ID: 32094488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]